文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

澳大利亚儿童长新冠负担及疫苗接种的潜在影响

Long COVID in children in Australia and the potential impact of vaccination.
PubMed 文献 · Vaccine · 2026-03-12

该研究利用2021—2022年6月龄至11岁儿童SARS-CoV-2感染诱导的血清流行率数据,采用非动态模型估算2021—2023年儿童长新冠负担,并评估不同疫苗接种覆盖率与疫苗有效性情景下的影响。结果显示,截至2022年底,5—11岁儿童血清流行率(85.6%)高于6月龄—4岁儿童(77.9%),但最小年龄组长新冠比例更高(约0.8% vs 约0.3%)。疫苗接种可减少儿童长新冠负担,应考虑纳入疫苗政策。

要点

  • 截至2022年底,5—11岁儿童血清流行率85.6%,6月龄—4岁儿童77.9%。
  • 最小年龄组长新冠比例约0.8%,高于5—11岁儿童的约0.3%。
  • 5—11岁组疫苗覆盖率40%在无免疫衰减假设下减少约13%长新冠患病率。

核心结论

  • 疫苗接种可减少儿童长新冠负担,应考虑纳入疫苗政策。

研究设计与样本

  • 使用SARS-CoV-2感染诱导数据估算2021—2022年6月龄至11岁儿童每月血清流行率。
  • 采用非动态模型,依据WHO长新冠定义和NASEM PCC定义使用年龄别PCC率估算2021—2023年长新冠负担。
  • 评估不同疫苗覆盖率和疫苗有效性情景下疫苗接种的影响。

主要发现

  • 截至2022年底,5—11岁儿童血清流行率85.6%,6月龄—4岁儿童77.9%。
  • 最小年龄组长新冠比例约0.8%,5—11岁儿童约0.3%。
  • 5—11岁组疫苗覆盖率40%在无免疫衰减假设下减少约9%感染和13%长新冠患病率。
  • 6月龄—4岁组若达到相同接种率,感染和长新冠患病率可分别减少约5%和10%。
  • 达到70岁及以上成人覆盖率94%可在两个儿科年龄组大幅减少感染(约32%—55%)和长新冠患病率(约34%)。

临床怎么用

  • 在疫苗政策制定中考虑儿童长新冠负担及疫苗接种的潜在减少作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long COVID (LC) or Post-COVID condition (PCC) is a serious illness that can result in chronic conditions in all ages, including children. We used SARS-CoV-2 infection-induced data to find monthly seroprevalence in 6 months to 11 year olds in 2021-2022 to estimate the proportion experiencing PCC. A non-dynamic model using age-specific PCC rates, in accordance with the WHO definition of LC and the National Academies of Sciences, Engineering, and Medicine (NASEM) definition of PCC, was applied to estimate the burden of LC in children during 2021-2023 and to evaluate the impact of vaccination under different coverage and vaccine effectiveness (VE) scenarios. By the end of 2022, seroprevalence was higher among children aged 5-11 years (85.6%) than among those aged 6 months-4 years (77.9%). However, a higher proportion of the youngest age experienced LC (approximately 0.8%), compared with children aged 5-11 year (approximately 0.3%). The low vaccination coverage achieved in the 5-11 age group (40%) averted approximately 9% of infections and reduced LC prevalence by 13% at the end of 2022 under the assumption of no waning VE. If children aged 6 months-4 years age group, who were ineligible for routine vaccination, had been vaccinated at the same uptake level, infections and LC prevalence could have been reduced by approximately 5% and 10%, respectively. Achieving coverage comparable to that of adults aged 70 years and older (94%) would have resulted in substantially larger reductions in infections (∼ 32%-55%) and LC prevalence (∼34%) in both paediatric age groups. However, assuming VE waning 12% per month, the reduction in seroprevalence and LC prevalence are limited to 2-4%, depending on coverage. These findings suggest that vaccination can reduce LC burden in children, which should be considered in vaccine policy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Costantino V, Notaras A, MacIntyre CR, et al. Long COVID in children in Australia and the potential impact of vaccination. Vaccine. 2026. PMID: 41825193. doi:10.1016/j.vaccine.2026.128442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。